Why the study?
Patients with diabetes have an increased risk of cardiovascular disease, heart failure, and chronic kidney disease, necessitating rapid implementation of therapies to reduce cardiovascular risk.
Systematic screening for ASCVD, heart failure, and CKD is essential in type 2 diabetes to allow early initiation of prognostic, guideline-directed therapies like SGLT2 inhibitors, GLP-1 RAs, and finerenone.
Screening for CVD in diabetes and diabetes in CVD patients warrants consideration; leaves open optimal protocols and outcomes data.
Patients with diabetes are at an increased risk of cardiovascular disease (CVD), including atherosclerotic CVD and heart failure. In addition, diabetes is associated with a higher risk of developing chronic kidney disease, which is considered to be one of the strongest risk factors for CVD and mortality. To address the increased cardiovascular risk of patients with diabetes, dedicated screening strategies for CVD are necessary; conversely, screening for diabetes needs to be performed in all patients with CVD to allow timely identification. Once diabetes is diagnosed, rapid implementation of treatment with therapies to reduce cardiovascular risk on top of standard of care is necessary. This review gives an overview of contemporary therapeutic strategies to reduce cardiovascular risk in patients with type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Berger et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: